drugset / Trial / NCT04212598

The Value of Sintilimab Consolidation Therapy After Definitive Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal Cancer

NCT04212598 ↗

Phase 2 Completed 40 enrolled Wuhan University
NaSingle-groupOpen-labelTreatment

Summary

Esophageal cancer is a kind of disease with high incidence and mortality. Definitive concurrent chemoradiotherapy is an important treatment for locally advanced esophageal squamous cell carcinoma. To Investigate the value of immunotherapy consolidation in locally advanced esophageal squamous cell carcinoma after completing radical concurrent chemoradiotherapy.

Timeline

Start
2020-08-03
Primary completion
2024-11-03
Completion
2024-11-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Sintilimab Monoclonal antibody — —